CA
ABBV icon

Continuum Advisory’s AbbVie ABBV Stock Holding History

Continuum Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44M Sell
13,684
-167
-1% -$35.9K 0.28% 81
2026
Q1 		$3.01M Sell
13,851
-64
-0.5% -$14.2K 0.29% 80
2025
Q4 		$3.18M Buy
13,915
+144
+1% +$32.8K 0.32% 76
2025
Q3 		$3.19M Sell
13,771
-35
-0.3% -$7.13K 0.34% 79
2025
Q2 		$2.56M Sell
13,806
-622
-4% -$116K 0.31% 79
2025
Q1 		$3.02M Buy
14,428
+23
+0.2% +$4.47K 0.39% 59
2024
Q4 		$2.56M Buy
14,405
+96
+0.7% +$17.6K 0.33% 77
2024
Q3 		$2.43M Buy
14,309
+604
+4% +$113K 0.31% 80
2024
Q2 		$2.35M Sell
13,705
-32
-0.2% -$5.3K 0.34% 73
2024
Q1 		$2.2M Buy
13,737
+5,107
+59% +$880K 0.33% 76
2023
Q4 		$1.34M Sell
8,630
-3,163
-27% -$461K 0.19% 137
2023
Q3 		$1.76M Sell
11,793
-24
-0.2% -$3.52K 0.28% 95
2023
Q2 		$1.59M Sell
11,817
-193
-2% -$28.3K 0.25% 106
2023
Q1 		$1.91M Buy
12,010
+1,106
+10% +$169K 0.32% 84
2022
Q4 		$1.76M Buy
10,904
+132
+1% +$20.2K 0.32% 87
2022
Q3 		$1.45M Buy
10,772
+453
+4% +$65K 0.26% 104
2022
Q2 		$1.58M Sell
10,319
-123
-1% -$18.8K 0.29% 100
2022
Q1 		$1.53M Buy
10,442
+751
+8% +$109K 0.29% 93
2021
Q4 		$1.31M Buy
9,691
+102
+1% +$12K 0.3% 84
2021
Q3 		$1.03M Sell
9,589
-611
-6% -$69.8K 0.28% 92
2021
Q2 		$1.15M Buy
10,200
+473
+5% +$53.3K 0.36% 71
2021
Q1 		$1.04M Buy
9,727
+354
+4% +$37.9K 0.43% 65
2020
Q4 		$1M Sell
9,373
-198
-2% -$19K 0.46% 62
2020
Q3 		$834K Buy
9,571
+5,388
+129% +$507K 0.46% 64
2020
Q2 		$415K Buy
4,183
+560
+15% +$49.3K 0.26% 84
2020
Q1 		$266K Buy
+3,623
New +$309K 0.18% 109

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Continuum Advisory's ABBV Position: Q2 2026 in Review

Continuum Advisory reduced its AbbVie (ABBV) stake by 1.2% in Q2 2026, selling an estimated $35.9K and leaving 13,684 shares worth $3.44M. The position accounts for 0.28% of the portfolio, ranked #81.

Continuum Advisory first reported a position in ABBV in Q1 2020 and has held it in 26 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Continuum Advisory held 13,684 shares of AbbVie worth $3.44M as of Q2 2026.
  • Continuum Advisory sold 167 AbbVie shares in Q2 2026, an estimated $35.9K.
  • AbbVie made up 0.28% of Continuum Advisory's portfolio in Q2 2026, its #81 holding.
  • Continuum Advisory first reported a position in AbbVie in Q1 2020 and has held it in 26 quarters since.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.